Recently, Tianjin Pharmaceutical Group Co., Ltd. (referred to as ‘Tianjin Pharma’) announced that Chen Hong, the company’s Vice General Manager, has resigned from his position due to personal reasons and will no longer hold any role within the company. According to the company’s disclosure, Mr. Chen’s departure will not affect the normal operations or management of the business. Tianjin Pharma stated that its corporate governance structure remains sound, its management team is stable, and all business activities are progressing as planned.During his tenure, Mr. Chen was primarily responsible for overseeing production operations and advancing certain strategic initiatives. His professional expertise and managerial experience contributed meaningfully to the company’s development. The Board of Directors expressed its gratitude for his dedication and contributions and extended best wishes for his future endeavors.As a well-established pharmaceutical manufacturer in China, Tianjin Pharma has been increasingly focused on the research, development, and production of innovative drugs, high-end generic medicines, and active pharmaceutical ingredients (APIs). This executive change is viewed as a routine personnel adjustment, and market observers generally believe it will not significantly impact the company’s long-term strategic direction. Investors are advised to monitor future company announcements and operational updates for comprehensive insights.
近日，津药药业股份有限公司（简称“津药药业”）发布公告称，公司副总经理陈洪因个人原因申请辞去所任职务，辞职后将不再担任公司任何职务。根据公司披露的信息，陈洪的辞职不会影响公司日常经营和管理工作的正常开展。津药药业表示，目前公司治理结构健全，经营管理团队稳定，各项业务有序推进。陈洪在任职期间，主要负责公司生产运营及部分战略项目的推进工作，其专业背景和管理经验曾为公司发展作出一定贡献。公司董事会对陈洪在职期间的辛勤付出和积极贡献表示感谢，并祝愿其未来事业顺利。津药药业作为国内知名的医药制造企业，近年来持续聚焦创新药、高端仿制药及原料药的研发与生产。此次高管变动属于正常人事调整，市场普遍认为不会对公司长期发展战略产生重大影响。投资者可继续关注公司后续公告及经营动态，以获取更全面的信息。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/17528.html